Latest HUMIRA Stories
ABBOTT PARK, Ill., April 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2011. Diluted earnings per share, excluding specified items, were $0.91, reflecting 12.3 percent growth.
BURLINGTON, Mass., Dec.
ABBOTT PARK, Ill., Nov.
BURLINGTON, Mass., Nov.
BURLINGTON, Mass., Oct.
BURLINGTON, Mass., Sept.
WALTHAM, Mass., Aug. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis.
LONDON, May 3, 2010 /PRNewswire/ -- The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. The cancer treatment Avastin had been widely expected to emerge as the biggest blockbuster drug following patent expiry...
ABBOTT PARK, Ill., April 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2010. Diluted earnings per share, excluding specified items, were $0.81, reflecting 11.0 percent growth, at the high end of Abbott's previously issued guidance range of $0.79 to $0.81.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.